The Motley Fool
27 Jun 2026, 16:49 UTC · 2h ago
What to Know About This $197,000 Veracyte Insider Sale After a 120% Stock Rally
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
The Motley Fool
27 Jun 2026, 16:49 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
2 claims · each scored for market impact
Veracyte has launched its Prosigna Breast Risk of Recurrence test in the U.S. to help personalize early-stage breast cancer treatment. — New product launches in the high-value oncology diagnostics market drive revenue growth and market share expansion.
+0.40Veracyte director Karin Eastham sold 3,729 shares of common stock on June 18, 2026. — While insider selling can be a negative signal, this was a small transaction executed under a pre-arranged 10b5-1 trading plan, minimizing its impact.
-0.10Which stocks this story touches
The company has seen a 120% stock increase and recently launched a new breast cancer risk test.
Continue reading
6 related stories
Search tags
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
The Motley Fool
2h ago
